Interspace Biosciences will implement a 1-for-5 reverse stock split to regain compliance with Nasdaq’s minimum bid price listing requirement. The reverse split became effective shortly after stockholders approved the measure, and the company began trading under the new ticker symbol IDXGD. Interspace said the action reduces outstanding common shares to 5.5 million from approximately 27.7 million and will eliminate fractional shares by rounding up to the next whole share. The company’s stated rationale links uplisting plans to attracting a broader investor base and supporting growth. While reverse splits are primarily corporate actions, they can influence investor access and liquidity for small-cap biotech—factors that shape the company’s ability to raise capital alongside program milestones.